Brimochol PF achieves endpoints in phase 3 presbyopia trial

May 4, 2023

Print

MORE NEWS

May 8, 2023
ASCRS Live: Visus Therapeutics shares data from Phase 3 pivotal study, BRIO-I
>
Learn more about our latest developments

Visus Therapeutics, Inc.
2 Nickerson St. Ste 101
Seattle, WA 98109

© VISUS THERAPEUTICS 2021 ALL RIGHTS RESERVED
VISUS THERAPEUTICS and BRIMOCHOL are trademarks of Visus Therapeutics, Inc.